Education
About Us
Working with TipRanks
Follow Us
Hansa Biopharma AB (SE:HNSA)
:HNSA
HNSA Stock Chart & Stats
kr36.94
-kr0.04(-0.17%)
At close: 4:00 PM EST
kr36.94
-kr0.04(-0.17%)
Day’s Range― - ―
52-Week Rangekr19.58 - kr42.98
Previous CloseN/A
Volume97.73K
Average Volume (3M)792.96K
Market Cap
kr3.76B
Enterprise Valuekr3.80B
Total Cash (Recent Filing)kr252.07M
Total Debt (Recent Filing)kr923.89M
Price to Earnings (P/E)―
Beta0.47
Next Earnings
Feb 05, 2026EPS Estimate
-1.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.75
Shares Outstanding101,763,220
10 Day Avg. Volume714,369
30 Day Avg. Volume792,961
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)-4.18
Price to Sales (P/S)14.38
P/FCF Ratio-3.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr94.00Price Target Upside154.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pipeline ExpansionImlifidase's ability to enable AAV-based gene therapies and promising data in Guillain-Barre Syndrome point to multiple potential indications that could expand long-term revenue opportunities.
Regulatory ApprovalIdefirix's conditional approval in Europe establishes a regulatory foothold that could facilitate wider clinician adoption and commercialization across transplant centers.
Transplant Clinical OutcomesPhase 3 ConfIdeS topline data showing improved kidney function and reduced dialysis dependency supports Idefirix's clinical value proposition and could encourage payer and clinician support.
Bears Say
Analyst Valuation PressureAnalyst model removals and downgraded expectations following trial setbacks reflect reduced investor confidence and could increase stock volatility until clinical or commercial clarity is achieved.
Commercial Uptake ChallengesUnderwhelming Idefirix sales and the suspension of pilot programs in key markets such as Germany indicate execution and access barriers that may slow commercial momentum.
Trial Design ConcernsUnexpected placebo responses and design limitations in the anti-GBM study raised doubts about the ability to demonstrate benefit in that indication, undermining development prospects.
Hansa Biopharma AB News
HNSA FAQ
What was Hansa Biopharma AB’s price range in the past 12 months?
Hansa Biopharma AB lowest stock price was kr19.58 and its highest was kr42.98 in the past 12 months.
What is Hansa Biopharma AB’s market cap?
Hansa Biopharma AB’s market cap is kr3.76B.
When is Hansa Biopharma AB’s upcoming earnings report date?
Hansa Biopharma AB’s upcoming earnings report date is Feb 05, 2026 which is in 3 days.
How were Hansa Biopharma AB’s earnings last quarter?
Hansa Biopharma AB released its earnings results on Oct 30, 2025. The company reported -kr1.75 earnings per share for the quarter, missing the consensus estimate of -kr1.737 by -kr0.013.
Is Hansa Biopharma AB overvalued?
According to Wall Street analysts Hansa Biopharma AB’s price is currently Undervalued.
Does Hansa Biopharma AB pay dividends?
Hansa Biopharma AB does not currently pay dividends.
What is Hansa Biopharma AB’s EPS estimate?
Hansa Biopharma AB’s EPS estimate is -1.64.
How many shares outstanding does Hansa Biopharma AB have?
Hansa Biopharma AB has 101,763,220 shares outstanding.
What happened to Hansa Biopharma AB’s price movement after its last earnings report?
Hansa Biopharma AB reported an EPS of -kr1.75 in its last earnings report, missing expectations of -kr1.737. Following the earnings report the stock price went down -11.027%.
Which hedge fund is a major shareholder of Hansa Biopharma AB?
Currently, no hedge funds are holding shares in SE:HNSA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hansa Biopharma AB
Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for use in sensitized kidney transplantations patients, as well as for anti-GBM antibody disease; and phase 2 clinical trial for antibody-mediated kidney transplant rejection and Guillain Barré syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the therapeutic potential of combining the two companies' IgG-modulating technologies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
HNSA Stock 12 Month Forecast
Average Price Target
kr94.00
▲(154.47% Upside)
Technical Analysis
BioInvent International AB
―
Saniona AB
―
Vicore Pharma Holding AB
―
Xspray Pharma AB
―
Cantargia AB
―
Options Prices
Currently, No data available
---